Drug intelligence / Profile preview

Safex-500

Development stage
Unknown
Lead developer
Vintage Labs
Modality
Small Molecules
Administration
Oral
01

Overview

Safex-500 is an oral antibiotic containing 500 mg of cefuroxime (likely as the prodrug cefuroxime axetil), a second-generation cephalosporin. Manufactured by Vintage Labs, it is indicated for the treatment of various bacterial infections, including respiratory tract infections (such as pneumonia and bronchitis), urinary tract infections, skin and soft tissue infections, and certain sexually transmitted diseases like gonorrhea. The drug's mechanism of action involves binding to penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This binding inhibits the final transpeptidation step of peptidoglycan synthesis, which weakens the cell wall and leads to bacterial cell lysis and death.

Brand names
Safex-500Safex500Safex 500Safex
Other names
cefuroxime axetilcefuroxime
02

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on Safex-500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Safex-500.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call